Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay
| Autor: | Leslie R. DeMars, B.-U. Sevin, Thomas J. Herzog, H. Schellhas, S. Hosford, Robert L. Coleman, Alan Wells, Holly H. Gallion, W.A. Christopherson |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Oncology Pathology medicine.medical_specialty Ovariectomy medicine.medical_treatment Risk Assessment Sensitivity and Specificity Disease-Free Survival Free interval Predictive Value of Tests Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Retrospective Studies Ovarian Neoplasms Chemotherapy business.industry Biopsy Needle Hazard ratio Obstetrics and Gynecology Middle Aged Prognosis medicine.disease Immunohistochemistry Predictive value Confidence interval Survival Rate Treatment Outcome Chemotherapy Adjuvant Drug Resistance Neoplasm Partial match Disease Progression Female Drug Screening Assays Antitumor Neoplasm Recurrence Local Ovarian cancer business Ex vivo |
| Zdroj: | International Journal of Gynecological Cancer. 16:194-201 |
| ISSN: | 1525-1438 1048-891X |
| DOI: | 10.1111/j.1525-1438.2006.00301.x |
| Popis: | The study objective was to determine the effectiveness of a phenotypic chemoresponse assay in predicting response to chemotherapy measured by progression-free interval (PFI) in a retrospective series of ovarian cancer patients whose tumor specimens had been tested with the ChemoFx assay. A statistically significant correlation between assay prediction of response and PFI was observed in 256 cases with an exact or partial match between drug(s) assayed and received. In 135 cases with an exact match, the hazard ratio for progression of the resistant group was 2.9 (confidence interval [CI]: 1.4-6.3; P0.01) compared to the sensitive group and 1.7 (CI: 1.2-2.5) for the intermediate compared to the sensitive group. The median PFI for patients treated with drugs assayed as resistant was 9 months, 14 months for those with drugs assayed as intermediately sensitive, and PFI had not been achieved for those with drugs assayed as sensitive. These data indicate that the ChemoFx assay is predictive of PFI in ovarian cancer. As the majority of ovarian cancers display different degrees of response to different chemotherapy agents ex vivo, the incorporation of assay information into treatment selection has the potential to improve clinical outcomes in ovarian cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text